Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | MAT2A | P31153 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798896 | 0.92 | TSHR (0.38) | ALDH1A1TSHRKDM4E | |
| SCHEMBL6802921 | 0.91 | ALDH1A1 (0.39) | TRPV4KCNH2HRH3MAT2AALDH1A1 | |
| SCHEMBL6797293 | 0.90 | L3MBTL1 (0.36) | TRPV4KCNH2HRH3MAT2AALDH1A1 | |
| SCHEMBL6797050 | 0.88 | ALDH1A1 (0.40) | TRPV4KCNH2HRH3ALDH1A1TSHR | |
| SCHEMBL6799493 | 0.85 | PPARD (0.35) | TRPV4CRHR1MAT2APPARDPPARA | |
| SCHEMBL6801139 | 0.82 | GRM5 (0.39) | ALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL6797814 | 0.81 | ALDH1A1 (0.38) | ALDH1A1TSHRL3MBTL1KDM4E | |
| SCHEMBL6801066 | 0.80 | LMNA (0.37) | ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL6801910 | 0.80 | L3MBTL1 (0.37) | ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL6800342 | 0.80 | TRPV4 (0.40) | TRPV4KCNH2HRH3CRHR1MAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028950-B1 | 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2003-05-02 | — | — | EP | claimed |
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | DOMAGALA JOHN MICHAEL (US) | 2002-08-22 | — | — | US | claimed |
| US-6825199-B2 | 7-Substituted quinazolin-2,4-diones useful as antibacterial agents | WARNER-LAMBERT COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1028950-B1 | 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | DOMAGALA JOHN MICHAEL (US) | 2002-08-22 | — | — | US | disclosed |
| US-6331538-B1 | TREATMENT OF BACTERIAL INFECTION | WARNER-LAMBERT COMPANY | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | NQO2, TOP1, TOP2A | TRPV4 2869/4885KCNH2 2104/4885HRH3 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.